• Describe the epidemiology and unmet need: When discussing a disease area or product, contextualizing the disease burden, diagnostic challenges, treatment gaps, and patient impact can significantly enhance engagement. Epidemiologic context helps frame why the science matters and how it may apply to clinical decision-making.
• Tailor scientific discussions: MSLs should customize discussions based on the interests, expertise, and role of the KOL or HCP. This may involve focusing on trial methodology with an investigator, safety management with a clinician, or care pathway integration with a health-system leader.
• Recognize the stakeholder’s environment: Practice constraints, patient demographics, institutional protocols, resource availability, and local treatment pathways can shape how data are interpreted and applied. Understanding these factors allows MSLs to engage in more relevant and practical scientific exchange.
• Listen before presenting: The most effective MSL interactions are often driven by thoughtful questions rather than slide-heavy presentations. Active listening allows the MSL to identify knowledge gaps, concerns, and opportunities for future scientific exchange.

Key Strategies for Tailored Engagement

1. Utilize Real-World Evidence Thoughtfully

Real-world evidence (RWE) has become an increasingly important component of medical decision-making, health technology assessment, post-authorization evidence generation, and medical strategy. RWE can help contextualize how therapies perform outside of controlled clinical trial settings, particularly in broader or more heterogeneous patient populations.

For MSLs, RWE can be valuable when discussing:

• Treatment patterns and sequencing in routine care
• Adherence and persistence
• Safety observations in broader populations
• Healthcare resource utilization
• Patient-reported outcomes and quality of life
• Outcomes in underrepresented or comorbid populations

However, RWE should be communicated with appropriate scientific rigor. MSLs should clearly describe the data source, methodology, population, endpoints, limitations, and potential biases. RWE should not be presented as a replacement for randomized controlled trial data unless supported by appropriate regulatory and scientific context. When discussing economic or comparative effectiveness RWE with population decision-makers (such as payers), presentations must align with FDA Section 114 (HCEI) criteria and rely on Competent and Reliable Scientific Evidence (CARSE).

For example, if an MSL is discussing a therapy with strong pivotal trial results, RWE may help answer practical questions such as: “How is this therapy being used in patients with multiple comorbidities?” or “What discontinuation patterns are being observed in routine practice?” These discussions can be highly valuable when conducted in a balanced, non-promotional, and evidence-based manner.

2. Emphasize Clinical Relevance

Scientific data become more meaningful when they are connected to real clinical decisions. When presenting efficacy, safety, or mechanism-of-action data, MSLs should help stakeholders understand the implications for patient care without overstating conclusions.

For example, rather than simply presenting a hazard ratio or response rate, an MSL can provide context by discussing:

• The patient population included in the study
• Key inclusion and exclusion criteria
• Comparator relevance to current standard of care
• Duration of follow-up
• Clinical significance versus statistical significance
• Safety considerations and monitoring requirements
• Applicability to local practice or treatment guidelines

This approach supports a more substantive dialogue and demonstrates that the MSL understands both the science and the realities of patient care.

3. Build Effective Feedback Loops

External engagement should be bidirectional. MSLs are not only responsible for communicating scientific information; they also play a critical role in gathering and communicating medical insights internally. These insights can inform evidence generation, publication planning, medical education, clinical trial strategy, patient support initiatives, and broader medical strategy.

High-quality insights typically go beyond a simple statement of preference. They identify a specific scientific, clinical, or operational need and explain why it matters. For example:

“Several community-based oncologists noted that although they are aware of the new biomarker testing recommendation, turnaround time and tissue availability remain barriers to implementation. They requested practical education on reflex testing workflows and interpretation of results.”

This type of insight is actionable because it identifies a stakeholder need, describes the barrier, and suggests an opportunity for medical affairs to support education or evidence generation.

To strengthen feedback loops, medical affairs teams should establish consistent processes for:

• Capturing insights in a structured format within dedicated Medical CRM platforms (firewalled from commercial sales data)
• Distinguishing individual opinions from recurring themes
• Identifying regional or institutional differences
• Sharing insights with appropriate internal medical stakeholders
• Closing the loop by demonstrating how insights informed strategic action

4. Segment Stakeholders Strategically

Not all stakeholders have the same needs, influence, or preferred engagement style. Strategic segmentation allows medical affairs teams to prioritize engagement based on scientific relevance, expertise, patient impact, research activity, guideline involvement, educational role, or involvement in healthcare decision-making.

Segmentation should not be viewed as a static ranking exercise. A stakeholder’s interests and influence may evolve over time based on new research involvement, changes in clinical practice, institutional leadership roles, or emerging therapeutic areas. MSLs should continually update stakeholder profiles based on compliant, objective, and relevant information.

Balancing Scientific Exchange with Compliance: Best Practices

Navigating the regulatory environment while fostering open scientific dialogue is a core competency for medical affairs. MSLs operate in a highly regulated space where the distinction between scientific exchange and promotional activity must be clearly understood and consistently maintained.

In the United States, medical affairs activities must be aligned with FDA expectations regarding truthful, non-misleading communication, appropriate handling of unsolicited requests, and avoidance of off-label promotion. In Europe and other regions, medical teams must also consider EMA-related expectations, local country codes, industry association rules, and national laws governing interactions with HCPs. Globally, teams must also remain attentive to anti-bribery and anti-corruption laws, privacy requirements, transparency reporting, and internal company policies.

Key Compliance Principles for MSL Engagement

• Use approved and appropriate resources: MSLs should use materials that have been reviewed and approved through the appropriate medical, legal, and regulatory process. Materials should be scientifically accurate, balanced, current, and consistent with the intended purpose. When responding to unsolicited medical information requests, MSLs should follow company procedures and provide information that is strictly responsive to the specific question asked.
• Maintain a clear non-promotional role: Medical affairs professionals should focus on scientific exchange, disease education, evidence discussion, and insight generation. MSLs should avoid sales-oriented language, comparative claims not supported by head-to-head evidence, or discussions that could be interpreted as promotional.
• Handle off-label questions appropriately: Off-label discussions require particular care. If an HCP asks an unsolicited question about off-label use, the MSL must formally log the request as unsolicited to maintain an audit trail. The MSL may then provide a truthful, balanced, scientifically rigorous response in accordance with company policy and applicable regulations. The response should be narrowly tailored to the request, appropriately documented, and separated from promotional activity or commercial involvement.
• Present data with balance and transparency: Balanced communication includes discussing both strengths and limitations of the evidence. This may involve addressing study design constraints, small sample sizes, subgroup limitations, immature survival data, missing data, confounding factors in observational research, or differences between trial populations and real-world practice.
• Disclose conflicts and follow transparency requirements: Interactions with KOLs, advisory board participation, consulting arrangements, congress activities, and research collaborations may trigger transfer-of-value reporting (e.g., U.S. Sunshine Act) or other disclosure obligations. MSLs should ensure engagements are conducted for legitimate scientific purposes, with appropriate documentation and fair market value (FMV) considerations when compensation is involved.
• Protect confidential and personal information: When collecting insights or discussing cases, MSLs must avoid capturing identifiable patient information unless there is a legitimate, approved process to do so. Privacy obligations such as HIPAA, GDPR, and local data protection laws should be respected. Stakeholder information must also be managed responsibly and in accordance with company privacy guidelines.

Strengthening Scientific Communication Skills

Scientific expertise alone is not sufficient for effective external engagement. MSLs must be able to communicate complex information clearly, adapt to different levels of expertise, and facilitate scientific dialogue without overwhelming the stakeholder.

Strong scientific communication includes the ability to explain data in a concise, accurate, and clinically meaningful way. For instance, when discussing a Kaplan-Meier curve, an MSL should be prepared not only to describe median outcomes and hazard ratios, but also to explain censoring, follow-up duration, confidence intervals, and whether proportional hazards assumptions are relevant. When discussing biomarker data, the MSL should be able to address assay methodology, cutoffs, sensitivity, specificity, and implications for patient selection.

Best Practices for Scientific Exchange

Effective MSL communication often follows a simple structure: understand the question, provide the relevant evidence, contextualize the data, acknowledge limitations, and confirm whether the information addressed the stakeholder’s need.

A strong scientific discussion typically includes:

• A clear objective for the interaction
• Stakeholder-specific framing
• Balanced presentation of benefits and risks
• Transparent discussion of evidence limitations
• Appropriate references to peer-reviewed literature or congress data
• Documentation of meaningful insights or follow-up needs

MSLs should also avoid common communication pitfalls, such as overloading stakeholders with excessive detail, using jargon without explanation, focusing only on favorable data, or failing to adapt when the stakeholder’s interest shifts.

Leveraging Omnichannel Engagement Strategies

The growth of digital platforms has transformed how medical affairs teams engage with stakeholders. An omnichannel approach uses multiple coordinated channels to deliver relevant scientific information and facilitate meaningful dialogue. Unlike a multichannel approach, where channels may operate independently, omnichannel engagement aims to create a consistent, connected stakeholder experience across in-person meetings, virtual interactions, email, webinars, congresses, medical information platforms, and digital content.

For medical affairs, omnichannel engagement should not simply mean “more touchpoints.” It should mean better-timed, more relevant, and more personalized scientific exchange based on stakeholder needs and preferences.

Webinars and Virtual Meetings

Virtual engagement has increased accessibility and efficiency, allowing MSLs to connect with stakeholders across geographies and time zones. Webinars, virtual advisory boards, and remote scientific discussions can be particularly useful for time-sensitive data dissemination, post-congress education, and engagement with stakeholders who have limited availability for in-person meetings.

However, virtual engagement should be designed intentionally. Effective virtual scientific exchange requires concise content, interactive elements, strong moderation, and clear objectives. Long slide presentations with limited discussion are less likely to generate meaningful engagement or insights.

Best practices include:

• Keeping presentations focused and evidence-based
• Using polling or structured questions when appropriate
• Allowing sufficient time for discussion
• Providing compliant follow-up materials
• Documenting insights and unanswered questions

Social Media and Digital Scientific Presence

Professional platforms such as LinkedIn can support scientific visibility, community building, and dissemination of disease-state or medical education content. However, social media use in medical affairs requires careful governance. Content must be accurate, balanced, compliant, and consistent with company policies. MSLs should be cautious about engaging in product-related discussions, responding to adverse event mentions, or commenting on off-label topics in public forums.

Medical affairs teams should have clear guidance on:

• What types of content may be shared
• How to handle unsolicited questions online
• How to identify and report adverse events or product complaints
• How to avoid promotional or misleading statements
• How to distinguish personal views from company-related communication

Congress Engagement

Medical congresses remain a central component of external engagement. They provide opportunities to discuss emerging data, understand shifts in scientific opinion, identify unmet needs, and engage with investigators and experts.

A strong congress strategy should include pre-congress planning, compliant engagement during the meeting, and structured post-congress follow-up. MSLs should understand key abstracts, late-breaking data, guideline implications, and anticipated stakeholder questions. After the congress, timely and tailored follow-up can help stakeholders interpret new information and apply it appropriately within the context of existing evidence.

Post-congress engagement may include scientific summaries, one-on-one discussions, internal insight sharing, and identification of potential evidence gaps. All materials and discussions should remain balanced, accurate, and aligned with approved medical processes.

KOL Engagement: From Transactional Interactions to Strategic Partnerships

KOL engagement is most effective when it is grounded in scientific credibility, mutual respect, transparency, and long-term value. The goal is not simply to increase interaction frequency, but to develop meaningful scientific relationships that support better understanding of disease, evidence gaps, and patient care needs.

A well-designed KOL engagement plan should define the purpose of engagement, stakeholder expertise, scientific objectives, anticipated value, and appropriate follow-up. Interactions should be documented in a compliant manner and aligned with the broader medical strategy.

Examples of High-Value KOL Engagement Activities

• Scientific exchange meetings: One-on-one or small-group discussions can help explore emerging evidence, clinical practice patterns, and unanswered scientific questions.
• Advisory boards: Advisory boards should have a legitimate scientific purpose, a clear agenda, appropriate participant selection, fair market value compensation where applicable, and robust documentation. The objective should be to obtain expert advice, not to influence prescribing.
• Investigator engagement: MSLs may support scientific discussions related to investigator-initiated studies (IIS), company-sponsored trials, site feasibility, enrollment barriers, or evidence gaps, in accordance with company policies and role definitions.
• Publication and evidence-generation discussions: Medical affairs teams may engage experts in discussions related to data gaps, publication needs, and scientific communication plans. These activities must adhere to GPP 2022 standards (Good Publication Practice), including appropriate authorship criteria, transparency, avoidance of ghostwriting, and full disclosure of conflicts of interest.
• Medical education support: MSLs can identify educational needs and support the development of scientifically balanced education initiatives, while ensuring appropriate separation from promotional activities and commercial influence.

Measuring the Impact of External Engagement

As medical affairs continues to evolve, demonstrating impact has become increasingly important. Traditional metrics such as number of visits or frequency of interactions are insufficient on their own. While activity metrics can help assess reach, they do not necessarily measure the quality or scientific value of engagement.

More meaningful measures may include:

• Quality of medical insights
• Stakeholder satisfaction and perceived scientific value
• Changes in understanding of unmet needs or evidence gaps
• Timeliness and relevance of scientific follow-up
• Contribution to evidence-generation strategy
• Support for clinical trial awareness or feasibility, where appropriate
• Identification of barriers in care pathways or diagnostic workflows
• Improved internal alignment around external scientific priorities

Medical affairs teams should combine quantitative and qualitative measures to understand engagement effectiveness. For example, a high number of interactions may be less valuable than fewer, more substantive discussions that generate actionable insights and inform strategic decisions.

Case Studies of Successful External Engagement

1. KOL Advisory Board on Evolving Treatment Pathways

A pharmaceutical company organized an advisory board to better understand how emerging clinical data could affect treatment sequencing in a complex therapeutic area. The meeting included academic experts, community clinicians, and health-system stakeholders to capture diverse perspectives.

Rather than relying on a one-way presentation format, the advisory board used structured case scenarios, interactive polling, and moderated discussion. Participants were asked to identify practical barriers to implementation, such as diagnostic testing delays, multidisciplinary coordination, and patient eligibility challenges.

The engagement produced several actionable insights. The medical affairs team identified a need for additional education on patient selection, greater clarity around safety monitoring, and further evidence generation in underrepresented patient populations. Participants reported higher satisfaction because the meeting was collaborative, scientifically rigorous, and directly relevant to clinical practice.

2. Post-Conference Data Dissemination

Following a major medical congress, an MSL team implemented a structured post-conference engagement plan. Rather than distributing a generic summary to all stakeholders, the team segmented follow-up based on stakeholder interests. Investigators received detailed trial design and subgroup analysis discussions, while community clinicians received practical summaries focused on patient selection, safety, and guideline context.

This tailored approach resulted in more meaningful follow-up discussions and increased stakeholder engagement. The team also captured recurring questions about treatment sequencing and biomarker testing, which informed future medical education and evidence-generation planning.

3. Real-World Evidence Discussion with Health-System Stakeholders

A medical affairs team engaged a regional health system to discuss real-world treatment patterns and outcomes in a chronic disease area. The MSL team presented peer-reviewed RWE alongside pivotal clinical trial data, clearly distinguishing between randomized evidence and observational findings.

The discussion revealed that formulary decision-makers were particularly interested in adherence, discontinuation drivers, and resource utilization. These insights helped the company better understand evidence needs from a health-system perspective and supported future planning for outcomes research. Importantly, the discussion remained non-promotional and focused on scientific evidence, methodology, and patient care considerations.

Integrating External Engagement with Medical Strategy

External engagement should be tightly connected to medical strategy. Insights from the field should inform strategic priorities, and strategic priorities should guide field engagement. This creates a continuous cycle in which medical affairs listens, learns, communicates, and adapts.

For example, if MSLs consistently hear that clinicians struggle with identifying appropriate patients for a therapy due to biomarker testing challenges, medical affairs may consider developing disease education, supporting diagnostic pathway research, or generating evidence on testing workflows. Similarly, if stakeholders express uncertainty about the interpretation of new subgroup data, medical affairs may prioritize balanced scientific education or further analysis where appropriate.

This integration ensures that engagement is not an isolated activity, but a central driver of evidence-based medical planning.

Building Capabilities for the Future

The future of external engagement will require MSLs and medical affairs professionals to combine deep scientific expertise with digital fluency, data literacy, strategic thinking, and strong communication skills. As artificial intelligence, advanced analytics, real-world data platforms, and personalized engagement tools become more common, medical affairs teams will need to use these capabilities responsibly and compliantly.

Key capabilities for future-ready MSLs include:

• Advanced interpretation of clinical trial and real-world data
• Understanding of health economics and outcomes research
• Digital and omnichannel engagement proficiency
• Strong insight generation and strategic communication
• Familiarity with regulatory and compliance frameworks
• Ability to engage diverse stakeholders, including payers, diagnostics experts, and patient advocacy groups
• Cross-functional collaboration while preserving medical independence

Professional development is essential. Structured training, mentoring, therapeutic area education, compliance refreshers, and recognized credentialing can help MSLs strengthen their effectiveness and credibility. For example, professional certification programs like the Board Certified Medical Affairs Specialist (BCMAS) program from the Accreditation Council for Medical Affairs (ACMA) can support career development by reinforcing core competencies in medical affairs, scientific communication, regulatory compliance, and strategic external engagement.

Conclusion

Elevating external engagement in medical affairs requires a multifaceted approach that includes understanding stakeholder needs, communicating science with clarity, maintaining compliance, leveraging omnichannel strategies, and integrating insights into medical strategy. For MSLs and medical affairs professionals, the objective is not simply to deliver information, but to enable meaningful scientific exchange that supports evidence-based healthcare decisions.

Successful engagement is grounded in trust, relevance, transparency, and scientific rigor. By tailoring discussions to stakeholder needs, using real-world evidence appropriately, maintaining strong compliance standards, and adopting thoughtful digital engagement strategies, medical affairs teams can build stronger relationships with healthcare stakeholders and generate insights that improve medical planning.

As the healthcare environment continues to evolve, teams must continually evaluate and adapt their external engagement strategies. Those that combine scientific excellence with strategic listening, compliant execution, and measurable impact will be best positioned to deliver value to stakeholders and ultimately support better outcomes for patients.

Frequently Asked Questions (FAQs)

• How can MSLs effectively balance compliance and scientific discussions?

MSLs can balance compliance and scientific exchange by using approved materials, providing balanced and accurate information, ensuring off-label responses are strictly unsolicited and formally logged, and adhering strictly to non-promotional boundaries. Regular training on FDA, EMA, local regulations, privacy requirements, and internal SOPs is essential.

• What role does real-world evidence play in engaging KOLs?

Real-world evidence helps contextualize clinical trial data by showing how therapies perform in routine practice. It provides insights into treatment patterns, adherence, safety, healthcare resource utilization, and outcomes in broader patient populations. MSLs should clearly explain the methodology, limitations, and appropriate interpretation of RWE, ensuring HCEI presentations to population decision-makers meet FDA Section 114 criteria.

• How can MSLs incorporate feedback to enhance their engagement strategies?

MSLs can incorporate feedback by capturing high-quality medical insights within dedicated Medical CRMs, identifying recurring themes, sharing insights with appropriate internal teams, and adapting future engagements based on stakeholder needs. Effective feedback loops help medical affairs refine education, evidence generation, and communication strategies.

• What tools or platforms can enhance omnichannel engagement?

Virtual meeting platforms, webinars, compliant email communication, medical information portals, congress engagement tools, customer relationship management systems (such as Veeva Medical), and professional digital platforms can all support omnichannel engagement. The key is to ensure that channels are coordinated, compliant, and aligned with stakeholder preferences.

• Why is it important to tailor discussions to individual stakeholders?

Tailoring discussions ensures that scientific information is relevant to the stakeholder’s role, expertise, patient population, and clinical or research priorities. Personalized engagement improves the quality of scientific exchange, strengthens trust, and increases the likelihood that discussions will generate meaningful insights.

• What makes a medical insight actionable?

An actionable medical insight identifies a specific unmet need, evidence gap, clinical barrier, or stakeholder concern that can inform medical strategy. It should provide enough context to guide next steps, such as education, research, data analysis, or stakeholder follow-up.

• How should MSLs approach advisory boards compliantly?

Advisory boards should have a legitimate scientific objective, appropriate expert selection, a clear agenda, balanced materials, fair market value compensation where applicable, and thorough documentation. They should be designed to gather expert input, not to promote a product or influence prescribing behavior.

• How can medical affairs measure external engagement success?

Medical affairs can measure success by evaluating the quality of insights, stakeholder satisfaction, relevance of scientific exchange, impact on medical strategy, contribution to evidence planning, and effectiveness of follow-up. Activity metrics such as number of interactions should be supplemented with measures of quality and strategic value.